IAS vs. RIGL

Last updated Jun 23, 2026

IAS (Integral Ad Science Holding Corp.) and RIGL (Rigel Pharmaceuticals, Inc.) are both stocks. IAS operates in Advertising Agencies (Communication Services), while RIGL operates in Biotechnology (Healthcare). At a 0.23 correlation, their price movements are largely independent.

Performance

IAS vs. RIGL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Integral Ad Science Holding Corp. (IAS) and Rigel Pharmaceuticals, Inc. (RIGL). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

IAS

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

RIGL

• 1D: 8.57%
• 1M: 23.16%
• YTD: -16.58%
• 6M: -19.09%
• 1Y: 88.75%
• 3Y*: 28.60%
• 5Y*: -3.32%
• 10Y*: 4.46%

*Multi-year figures are annualized to reflect compound growth (CAGR)

IAS vs. RIGL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
IAS Integral Ad Science Holding Corp.	0.00%	-0.96%	-27.45%	63.71%	-60.42%	0.95%
RIGL Rigel Pharmaceuticals, Inc.	-16.58%	154.64%	16.00%	-3.33%	-43.40%	-40.45%

Correlation

The correlation between IAS and RIGL is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.06
Correlation (3Y) Calculated over the trailing 3-year period	0.22
Correlation (All Time) Calculated using the full available price history since Jun 30, 2021	0.23

The correlation between IAS and RIGL shifts across timeframes, from 0.06 (1 year) to 0.23 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap IAS : $1.76B RIGL : $703.38M
EPS IAS : $0.28 RIGL : $19.21
PE Ratio IAS : 37.31 RIGL : 1.86
PEG Ratio IAS : 0.22 RIGL : 0.00
PS Ratio IAS : 2.95 RIGL : 2.26
PB Ratio IAS : 1.59 RIGL : 1.76
Total Revenue (TTM) IAS : $590.67M RIGL : $299.77M
Gross Profit (TTM) IAS : $457.31M RIGL : $279.95M
EBITDA (TTM) IAS : $119.85M RIGL : $125.80M

Return for Risk

IAS vs. RIGL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IAS

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

RIGL

RIGL Risk / Return Rank: 75
RIGL Sharpe Ratio Rank: 78
RIGL Sortino Ratio Rank: 79
RIGL Omega Ratio Rank: 78
RIGL Calmar Ratio Rank: 73
RIGL Martin Ratio Rank: 68

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IAS vs. RIGL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Integral Ad Science Holding Corp. (IAS) and Rigel Pharmaceuticals, Inc. (RIGL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	IAS	RIGL	Difference
Sharpe ratio: Return per unit of total volatility	—	1.27	—
Sortino ratio: Return per unit of downside risk	—	2.18	—
Omega ratio: Gain probability vs. loss probability	—	1.27	—
Calmar ratio: Return relative to maximum drawdown	—	1.78	—
Martin ratio: Return relative to average drawdown	—	3.09	—

Drawdowns

Drawdown Indicators

	IAS	RIGL	Difference
Max Drawdown Largest peak-to-trough decline	—	-99.37%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-50.08%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-57.00%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-85.24%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-86.40%	—
Current Drawdown Current decline from peak	—	-96.66%	—
Average Drawdown Average peak-to-trough decline	—	-90.91%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	28.85%	—

Volatility

Volatility by Period

	IAS	RIGL	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	10.60%	—
Volatility (6M) Calculated over the trailing 6-month period	—	37.45%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	70.20%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	85.53%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	82.86%	—

Dividends

IAS vs. RIGL - Dividend Comparison

Neither IAS nor RIGL has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

IAS vs. RIGL - Profitability Comparison

The chart below illustrates the profitability comparison between Integral Ad Science Holding Corp. and Rigel Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

IAS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Integral Ad Science Holding Corp. reported a gross profit of 118.81M and revenue of 154.36M. Therefore, the gross margin over that period was 77.0%.

RIGL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a gross profit of 54.21M and revenue of 58.82M. Therefore, the gross margin over that period was 92.2%.

IAS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Integral Ad Science Holding Corp. reported an operating income of 7.57M and revenue of 154.36M, resulting in an operating margin of 4.9%.

RIGL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported an operating income of 11.89M and revenue of 58.82M, resulting in an operating margin of 20.2%.

IAS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Integral Ad Science Holding Corp. reported a net income of 7.05M and revenue of 154.36M, resulting in a net margin of 4.6%.

RIGL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a net income of 8.65M and revenue of 58.82M, resulting in a net margin of 14.7%.

Frequently Asked Questions

Can I hold both IAS and RIGL in my portfolio?

IAS and RIGL have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.